Webb1 dec. 2024 · Most common adverse reactions observed in a clinical trial of RVVC were headache, abdominal pain, diarrhea, nausea, urinary tract infection and fatigue. To report … WebbSCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark. Read More > 03/31/23 SCYNEXIS Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update.
SCYNEXIS Skyrockets on Teaming Up With GSK for Fungal …
Webb글락소스미스클라인社는 동종계열 최초 항진균제 ‘브렉사펨’(Brexafemme: 아이브렉사펀저프 정제)를 외음질 칸디다증(VVC) 치료 및 재발성 외음질 칸디다증(RVVC) 감소 용도로 발매할 수 있는 독점적... Webb4 apr. 2024 · GSK will provide Scynexis with an upfront payment of $90m (€83m), and a potential $503m in additional payments based on certain milestones, including regulatory approvals and sales targets. Scynexis will retain its right to develop all other assets derived from enfumafungin, and GSK will have the right of first negotiation to these potential … marriage records database south africa
CMCSA: 3 Top-Rated Companies to Buy Today - stocknews.com
Webb20 okt. 2024 · SCYNEXIS has initiated the launch of its second commercial product in the U.S., BREXAFEMME ® (ibrexafungerp tablets). The U.S. Food and Drug Administration … WebbTell your healthcare provider about all the medicines you take. The most common side effects of BREXAFEMME include loose stools, nausea, stomach pain, dizziness, and vomiting. Call your doctor for medical advice about side effects. You may report side effects to SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA … Webb2 dec. 2024 · Scynexis, Inc. announced that the FDA has approved a second indication for Bexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) The approval is based on positive results from the pivotal Phase III CANDLE study that evaluated the safety and efficacy of monthly dosing of … marriage records dallas texas